DTx Podcast with Eugene Borukhovich

Welcome to another insightful episode of the DTx Podcast, where we dive into the evolution and expansion of digital therapeutics. As we discussed in our previous episode with Mike Pace, 2023 was a really tough year for DTx. With the significant developments in the industry so far in 2024, we felt it was important to update our community on the positive tailwinds we’ve seen in advancing much-needed digital therapies for patients. Host Eugene Borukhovich engages in a thought-provoking discussion with esteemed guests Dr. Jenna Carl, Andy Molnar, Marty Culjat, and Kirsten Tullia. The panel delves deep into the positive advancements and potential challenges within the DTx industry, offering their unique expertise and perspectives. [00:30] How is the expanding distribution channel in the US, including health systems, expected to impact the accessibility of digital mental health programs if new codes are finalized? [05:15] What are the tactical questions and nuances surrounding combining software with wearables or medical devices, and the potential consequences on commercial models? [12:45] What impact do the proposed expansion of coverage for digital mental health technology devices (DMHT) have on Medicare, Medicaid, and other healthcare systems, and what changes are expected in terms of operational plans for distributing and reimbursing digital mental health programs? [18:10] How is the transition to using digital therapeutics expected to continue evolving, and what are the anticipated challenges in terms of reimbursement and coverage policies? [23:30] What key factors contribute to the perceived impatience of investors in the market, and how does this influence the R&D cycles and push for further investments in new innovative digital therapies? [28:00] How important is Medicare reimbursement in attracting investor interest, and what are the potential proof points needed to bolster confidence in personalized and integrated solutions within the digital therapeutics industry? Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders. If you’d like to learn more about sponsorship opportunities across Mission Based Media assets, visit our website at https://missionbasedmedia.com/ Guest Links and Resources: Connect with Dr. Jenna Carl on Linkedin Connect with Andy Molnar on Linkedin Connect with Marty Culjat on Linkedin Connect with Kirsten Tullia on Linkedin Listen to the episode with Mike Pace Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode of the DTx Podcast, Eugene Borukhovich sits down with Mike Pace, CEO and founder of PalmHealthCo, to delve into the latest developments and insights from the DTx industry from 2023 and to discuss what may be in store for 2024. Eugene and Mike cover various aspects of the DTx landscape, including the growing importance of FDA authorizations, the shift towards non-prescription solutions, and the maturation of the industry into operations and pricing. Learn more about the impact of FDA authorizations on scalability in the US healthcare system, the strategic integration of digital therapeutics with virtual care models, market consolidation, and the effects of decreased venture funding on the industry. 1. [04:00] What has the industry learned from Pear Therapeutics' initial growth and scaling and, ultimately, its bankruptcy? 2. [10:45] Mike mentions the importance of FDA authorizations for scalability in the US healthcare system. How does he foresee potential FDA approvals shaping the landscape for digital therapeutics in the near future? 3. [15:20] PalmHealthCo has been involved in integrating DTX with virtual care and pushing for a virtual first go-to-market model. How has this approach impacted their journey and success in the DTx space, and what are the potential implications for the industry as a whole? 4. [20:10] What is the importance of high-quality clinical evidence for achieving permanent listing under regulatory laws? How critical is this evidence generation for the future of digital therapeutics, and what challenges does Mike anticipate in this regard? 5. [25:40] Considering the rise of aggregators in the healthcare industry influencing the market for digital therapeutics, what strategies can DTx companies employ to navigate this evolving landscape? 6. [30:15] With the current state of venture funding and market consolidation in digital health, what advice does Mike have for startups in terms of maintaining a focus on positively impacting patients and families while navigating the industry's challenges? Tune in to the DTx Podcast to gain valuable insights into the evolving world of digital therapeutics and stay updated on the latest trends, legislative impacts, and entrepreneurial advice from industry leaders. Guest Links and Resources: Connect with Mike Pace on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode of the DTx Podcast, Eugene Borukhovich hosts Philip Heimann, CEO of Vivira, a prominent player in the DTx landscape in Germany. "The genesis of Vivira was the need for personalized movement therapy - we wanted to provide people with a solution that was made just for them," says Philip.  This necessity led to the development of an innovative digital therapeutic solution that has made a significant impact in the market. Eugene and Philip dive into the profound impact of the DiGA law in Germany, passed in 2019, on Vivira's market growth. This legislation enabled general reimbursement and physician involvement in prescribing the app, marking a pivotal turning point for the company and the broader DTx landscape in Germany. In addition, Philip sheds light on the challenges faced by DTx startups in understanding the market complexities and securing suitable funders. He stresses the importance of selecting investors who can offer long-term support and emphasizes the significance of focusing on long-term goals and building high-value companies. 1. [05:30] What challenges did Vivira face in the early stages, being almost exclusively angel-funded, and how did this contribute to the development of their DTx solution? 2. [10:45] What pivotal role has the DiGA law played in enabling Viveira's growth in the market, and what are the implications of this legislation for other DTx companies in Germany? 3. [15:20] How has Vivira's approach of not starting in the direct-to-consumer market and focusing on the DIGA prescription model influenced its journey and success in the DTx space? 4. [20:10] What is the significance of high-quality clinical evidence, particularly RCT studies, for achieving permanent listing under the DiGA law? 5. [25:40] What are the challenges and potential solutions regarding the activation of digital therapies prescribed by doctors? 6. [30:15] As a serial entrepreneur, what critical advice does Philip have for DTX startups in navigating the complexities of the market and choosing investors? Join us on the DTx Podcast for valuable insights into the world of digital therapeutics, covering topics from legislative impacts to entrepreneurial advice. Subscribe now to stay updated on the latest episodes and continue exploring the dynamic realm of DTx. Guest Links and Resources: Connect with Phillip Heimann on LinkedIn Visit Vivira Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Josh Sackman, President and Co-founder of AppliedVR. AppliedVR, in their own words, provide virtual reality-based treatments that represent a comprehensive approach to chronic pain that empowers patients with accessible digital tools self-managed in their own home. In this episode, we cover: The origin story of AppliedVR Transitioning from an app store for health VR to focus pain management market Patient experience and the pain management pipeline Funding journey and key funding milestones The scientific hypothesis of "mind over matter" behind AppliedVR's approach and evidence generation journey The FDA approval process for AppliedVR and lessons learned for entrepreneurs. AppliedVR's current business hypothesis and scaling plan Market channels and scaling VR Guest Links and Resources: Connect with Josh Sackman on LinkedIn Visit www.appliedvr.io Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this replay episode, we hear from Sylvain Piquet, COO and Co-founder of Five Lives, the app that leverages the new science of brain aging, neuroplasticity, and cognitive reserve to help people improve their brain health and prevent cognitive decline and dementia. In this episode, we cover: The origin story of Five Lives and the motivation behind focusing on dementia and cognitive decline. The demographics benefitting from using Five Lives Gamifying behaviour change Evidence generation and funding journey The advantages of direct-to-consumer distribution through the app store How digital therapeutics can fit within the NHS The challenges of implementing DTx across UK, French, and German markets Guest Links and Resources: Connect with Sylvain Piquet on LinkedIn Visit www.fivelives.health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In honor of Gift of Sight month we're replaying this insightful episode with Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Vijay Ravindran, founder and CEO of Floreo. Floreo allows therapy to be more engaging and happen anywhere, assisting people in practicing critical social skills at their own pace through immersive experiences, starting with adolescent Autism spectrum disorder. In this episode, we cover: The founding story of Floreo Market for autism and neurodiversity The child and caregiver experience using Floreo Funding journey and key milestones User and caregiver experience using Floreo Scientific hypothesis and evidence generation journey Scaling virtual reality in healthcare Guest Links and Resources: Connect with Vijay Ravindran on LinkedIn Visit floreovr.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

We're seeing a broader consolidation of digital health solutions this year to bring together the amazing talentand the scientifically validated assets to drive scale in the market and improve unit economics. On the heels of last week's announcement of the merger between Fern Health and BehaVR tune into this replay episode to hear Eugene Borukhovich's conversation withwith Aaron Gani, Founder and CEO of BehaVR. BehaVR translates proven science into immersive and engaging XR therapeutics for mental and behavioral health. In this episode, we cover: Origin Story: Aaron Gani shares the origin story of BehaVR, starting from its inception in 2016 and the inspiration behind creating immersive XR therapeutics for mental and behavioral health. Funding Journey and Milestones: Walk through BehaVR's funding journey, uncovering the key milestones achieved with each funding round and how it has shaped the company's growth and impact in the digital therapeutics landscape. Patient Journey Using VR: Gain insights into the end customer experience offered by BehaVR, highlighting the effectiveness of immersive therapeutics in supporting mental well-being. Scientific Hypothesis and Evidence Generation: Explore the hypothesis that BehaVR is built upon and learn how their evidence generation journey is proving the effectiveness of their immersive XR therapeutics, showcasing the power of mind-body connections. Merging with OxfordVR and FDA Approval: Discover the decision-making process behind BehaVR's merger with OxfordVR and their journey towards FDA approval. Business Hypothesis and Scaling Plan: Delve into BehaVR's current business hypothesis and explore their scaling plan. Partnership with Sumitomo Dainippon: Aaron expands on BehaVR's partnership with Sumitomo Dainippon and discusses the commercial arrangement that led to this collaboration. Access to Care: Explore the accessibility of virtual reality therapy and its role in improving access to care for patients. Pear Therapeutics and the Future of PDTs: Aaron shares his thoughts on Pear Therapeutics and discusses the future of Prescription Digital Therapeutics (PDTs), providing insights into the evolving landscape of digital therapeutics and its potential to revolutionize mental health care. Guest Links and Resources: Connect with Aaron Gani on LinkedIn Visit BehaVR Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from, Rich Brancaccio, Chief Innovation Officer of Revibe Technologies, and Lindsay Ayearst, Chief Scientific Officer of Revibe Technologies. In their own words, Revibe is a digital therapeutics company fusing behavioral science with technology and currently developing a new digital therapy for ADHD. In this episode, we cover: Founding story and funding milestones Child and caregiver experience using Revibe Quantifying attention & capturing focus data Evidence generation journey & clinical endpoints The ADHD market choice to focus on adolescent ADHD Lessons learned from the first wave of similar products and companies OTC vs PDT Guest Links and Resources: Connect with Lindsay Ayearst on LinkedIn Connect with Rich Brancaccio on LinkedIn Visit www.revibetech.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics. Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question. Guest Links and Resources: Connect with Brent Vaughan: LinkedIn Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Chan Yoon, MD, CEO of EverEx. EverEx is revolutionizing musculoskeletal rehabilitation with cutting edge AI, pose estimation technology, and evidence based treatments. In this episode, we cover: Insights into Digital Health in South Korea The EverEx creation journey The musculoskeletal health market in South Korea  Funding journey and challenges in the market Reimbursement environment in South Korea Entering the US Market with the product EverEx Rehab Clinical trials and patient experience using EverEx products Guest Links and Resources: Connect with Chan Yoon on LinkedIn Visit Everex.kr Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that’s exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to “help people change some of those core beliefs, which then directly influence what we do on a day to day basis.” And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT – Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What’s next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Francesca Wuttke, Founder and CEO of Nen who is focusing on building prescription digital therapeutic at a cross-section of pediatrics, pain with an initial focus in oncology. In this episode, we cover: The background to nen and naming the company Gamifying CBT for treating children's pain Targeting the psychological aspects of pain Treating unmet needs in oncology Patient and parent experience Clinical evidence generation and PDT Business hypothesis, market entry, pricing and reimbursements Guest Links and Resources: Connect with Francesca Wuttke on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Curio has announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial demonstrating that MamaLift Plus has met its efficacy endpoints. This is a significant step towards providing better support for mothers during a crucial time.  In this Replay episode we hear from Shailja Dixit, CEO of Curio. In their own words: 'Curio is a Digital Therapeutics company with tailor-made Cognitive Behavioral Therapy programs for Women across the cycle of life – encompassing age groups, physiological conditions and social settings'. Topics include: The Founding Story of Curio Using Digital to Destigmatize Mental Health Support User experience of the MamaLift product Combining methods of Cognitive Behavioural Therapy, Interpersonal Therapy and Behavioural Activation Therapy  PDT vs Physician recommended DTx  Guest Links and Resources: Connect with Shailja Dixit on LinkedIn Visit https://www.curiodigitaltx.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | LSI | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this special feed drop hear Eugene Borukhovich in conversation with Pharmaphorum Editor in Chief Jonah Comstock discussing what they saw and heard at DTx East in Boston. This year the digital therapeutics space took a hit with the downfall of Pear Therapeutics, one of the most well-known of the industry’s still-active pioneers. Combined with Akili Interactive’s hard pivot to OTC , some in the industry are wondering whether standalone prescription digital therapeutics are a failed experiment. Pharmaphorum Links and Resources: Connect with Jonah Comstock on LinkedIn Visit pharmaphorum.com Episode Write Up Pharmaphorum Podcast DTx Podcast Links and Resources:: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Andrew Jenkinson and Niall O'Driscol, CEO's and Co-founders of vStream. vStream's primary focus is on the creation of compelling and engaging patient-centric experiences. Specializing in virtual reality, augmented reality, mixed reality, 360 video, immersive experiences, and digital installations Topics include: The background to vStream and the product ShineVR The funding journey Competition and the overall market in virtual reality Patient experience using ShineVR incorporating proven CBT techniques in a number of different spaces Scientific hypothesis and evidence generation process The proposition to employers for for corporate wellness Scaling plan and future pipeline Insights from a patient using ShineVR Guest Links and Resources: Connect with Niall O'Driscoll on LinkedIn Connect with Andrew Jenkinson on LinkedIn Visit vStream Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

If you’ve been keeping up with the news you’ll know that since March this year, Kranus Edera has been permanently listed as a digital health application by the Federal Institute for Drugs and Medical Devices. But the journey did not stop there. Last week Kranus Health achieved another milestone: successful price negotiations with the GKV-Spitzenverband, which is in charge of negotiating the reimbursement amount for new medications from pharmaceutical manufacturers. Kranus Edera has now secured one of the highest permanent reimbursement prices ever recorded for a DiGA in Germany: €235 (incl. VAT). To provide some context for this exciting development we’re revisiting our episode with Jens Noertershaeuser, Founder & Co-CEO of Kranus Health. In their own words, Kranus Health’s mission is to revolutionize men's health by providing innovative and accessible healthcare solutions. As one of only 10 companies with a permanent approval, Kranus Edera is the only the first digital health app (DiGA) for the treatment of erectile dysfunction. In this episode, we cover: The background to Kranus Health The focus on men’s health and erectile dysfunction as a flagship product Products in development and the future of Kranus Health The funding journey Patient experience using the product Evidence generation and the DiGA process Insurance company reimbursment Guest Links and Resources: Connect with Jens Noertershaeuser on LinkedIn Visit kranushealth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Meri Beckwith, Co-founder of Lindus Health. In their own words, Lindus delivers end to end clinical trials for health tech and biotech pioneers. Topics include: The background and inception story of Lindus Health Lindus Health's place in the value chain Key funding milestones and achieving in a difficult market enviroment The unique aspects of clinical trials for DTx DTx as a medical device Pharmaceutical cclients in the DTx market The future for clinical trials and digitization Guest Links and Resources: Connect with Meri Beckwith on LinkedIn Visit Lindus Health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Susa Monacelli, General Manager at Propeller Health. In their own words Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. Topics include: The background to Propeller Health and the ResMed umbrella The original business hypothesis of ResMed and how this has evolved Patient experience using Propeller Health Differentiating propositions to health system, pharma and payers DTx vs. Disease Management 2.0 The future of prescription digital therapeutics Partnerships with health systems vs other routes to patient access Challenges holding the digital health industry back Guest Links and Resources: Connect with Susa Monacelli on LinkedIn Visit Propeller Health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Have you heard? On August 22, Mahana Therapeutics announced a distribution and marketing partnership with Bayer’s consumer health division. This partnership unites Mahana’s proficiency in digital therapeutic advancement with Bayer’s commitment to empowering individuals through cutting-edge digital solutions, all aimed at enabling greater personal health control. The full press release is linked below. In light of this, we’re bringing you this replay episode with Simon Levy, CEO and Co-founder, and Ann Montgomery, Chief Product Officer at Mahana. In their own words, Mahana develops digital treatments for people living with chronic health conditions, and their first treatment, Mahana for IBS, is now available as an FDA-cleared app. In this episode, we cover: The founding story and funding journey of Mahana Complexities of the end to end patient experience The freemium model and how that translates into a PDT Evidence generation and FDA clearance process Scaling plans for PDTs Guest Links and Resources: Press Release about the Mahana and Bayer partnership Connect with Simon Levy on LinkedIn Connect with Ann Montgomery on LinkedIn Visit Mahana.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Brian Wallace, CMO and Co-Founder of Calmsie. Calmsie in their own words are empowering children to develop emotional resilience from an early age. Calmsie creates engaging DTx video games designed to improve outcomes for children with depression and anxiety. In this episode, we cover: Translating addiction science to treat depression and anxiety in children The origin story and funding journey to Calmsie Parent and child experiences using the gamified program Emotional resilience training for prevention of mental health issues How the Calmsie video game affects the brain Evidence generation and deciding on PDT vs non-PDT routes The free workbook helping children understand the war in Ukraine Guest Links and Resources: Connect with Brian Wallace on LinkedIn Visit calmsie.ai YourCoach Health: Deep Dive Into Adolescent Health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this special feed drop hear the first episode of Emerging Medtech Today, hosted by Henry Peck and powered by LSI. The Emerging Medtech Today podcast offers a unique opportunity to gain valuable insights from industry leaders who are building breakthrough businesses that are moving medtech forward. Join Henry as he engages in captivating conversations with innovators and investors who are at the forefront of medtech. Discover the strategies, technologies, and ideas that are shaping the future of healthcare.  In this episode Henry Peck speaks with Diana Saraceni and Alessio Beverina, co-founders and managing directors of Panakes, a venture capital firm that’s helping to build the next generation of game-changing technologies companies in the field of Life Sciences. Diana brings 23 years of venture capital experience and previously co-founded another successful venture capital firm called 360 Capital. Alessio, with an engineering background, co-founded Panakes in 2015 after working as a research engineer at Sofinnova Partners. Throughout the episode, Diana and Alessio provide valuable insights into the evolving landscape of medtech investing, shedding light on the complexities, challenges, and opportunities in the field. Topics include: Current market conditions and challenges faced by companies in medtech Key learnings from Panakes’ first fund which focused on medtech and raised €75 million Strategies for the newly raised second fund, with plans to expand its focus to include biotech and opportunities where medtech and biotech converge The impact of regulatory changes, particularly the MDR (Medical Device Regulation) shift and the increasing prioritization of FDA approval in Europe   Navigating the evolving landscape of digital health and its intersection with artificial intelligence (AI) Health tech and digital health opportunities in Europe compared to the US A reflection on the future of healthcare innovation Diana and Alessio’s upcoming participation at the LSI Europe ‘23 conference in September, where they will discuss these topics in greater detail And more! Transcript of episode Guest links and resources: Connect with Diana Saraceni: LinkedIn Connect with Alessio Beverina: LinkedIn | Twitter Panakes Connect with Henry: Twitter | LinkedIn Learn more about LSI Sign up for LSI Europe '23 Connect with LSI: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect with Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from David Kim, Managing Director at DigiTx Partners. In their own words DigiTX Partners is a venture firm focused on investing in and supporting supporting early stage startup companies in the digital health space. Launched in 2016 as a joint venture by Astellas Pharma And MPM Capital, DigiTx Partners remains one of a few venture funds exclusively dedicated to the digital health space. In 2018, Astellas continued its endeavor in digital health by forming the Rx Plus Digital Fund with DigiTx Partners as its investment manager. In this episode, we cover: What are the challenges faced by digital therapeutics in terms of distribution and clinical workflow? What hypothesis does DigiTx on DTx? What are the benefits of standalone vs drug+? Are DigiTx tracking any other modalities? What lessons have DigiTx learned so far? What will be the drivers for new capital injections in DTx especially? What are investors looking for ? What will the drivers of success going forward be for DTx?  How will the role of doctors, nurse & pharmacists change in order for the industry overall to scale PDT's? Guest Links and Resources: Connect with David Kim on LinkedIn Visit DigiTx Partners Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Sean Khozin, Senior Partner at the investment firm Braven Partners. He focuses on advancing in innovations at the intersection of biology, technology and AI. Sean was previously the CEO of CancerLinQ and the Global Head of Data Strategy and Data Science at Johnson & Johnson. He had a successful tenure in the US federal government as the associate director of FDA’s Oncology Center of Excellence and the founding executive director of FDA INFORMED, a data science and technology incubator he established under special authorities from the US department of health and human services. Topics include: How are Braven Partners incubating and supporting minimally viable ecosystems of companies that can make a difference? What are the goals of the Alliance for Artificial Intelligence in Healthcare? How can digital therapeutics developers ensure effective reimbursement for their products in the healthcare industry? How is the ethos of AI in healthcare speaking to a culture that is focused on safety without compromising innovation? How do we demystify new tools and technologies such as AI? How does the FDA think about regulating AI? What can digital therapeutic manufacturers companies, entrepreneurs and trailblazers learn from the Alliance for Artificial Intelligence in Healthcare (AAIH)? Guest Links and Resources: Connect with Sean Khozin on LinkedIn Visit Braven Partners Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Benjamin Alouf, MD, Chief Medical Officer at Limbix. In their own words, Limbix is the first digital therapeutic for adolescent depression.  Big Health, the leading provider of non-drug digital treatments for mental health, has now acquired Limbix. In addition to health care providers, SparkRx will be made available to Big Health’s employer, public sector, health systems and health plan customers, and through the company’s strategic distribution agreements with pharmacy benefit managers (PBMs), significantly increasing nationwide access. In this episode, we cover: Origin of the company and story behind the name 'Limbix' The funding journey and key milestones achieved The choice to focus on the young adult population in particular Patient experience with SparkRx Defining good patient engagement in adolescent mental health Evidence generation and FDA submission process Business hypthothesis and scaling plan The future of the PDT market Guest Links and Resources: Connect with Benjamin Alouf, MD on LinkedIn Visit Limbix.com Episode PDF Big Health Expands into Adolescent Mental Health Through Acquisition of Limbix Host Links: Eugene Borukhovich: Twitter | LinkedIn Chandana Fitzgerald, MD: Twitter | LinkedIn YourCoach.health: Website | Twitter Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Eddie Martucci, co-founder and CEO of Akili. In their own words, Akili Interactive is a leading digital health company combining scientific and clinical rigor with ingenuity of the tech industry to reinvent medicine. In this episode, we cover: What factors have led to the increase in market demand for non-drug treatments for adult ADHD? How does Akili Interactive's prescription video game product, EndeavorRx, differ from traditional behavioral therapy for ADHD? What are the advantages and challenges of developing a digital therapeutic product that is available over-the-counter (OTC) without a prescription? How does the insurance coverage landscape impact the availability and adoption of digital therapeutics? What strategies does Akili Interactive employ to address the lack of awareness about digital therapeutics and their potential benefits? How does the user interface and experience of the EndeavorRx companion app, EndeavorRx Insight, contribute to higher compliance and better outcomes for families? How has Akili Interactive adapted and improved their commercial platform for scaling the distribution of their products? What advice does Eddie Martucci have for health executives? Guest Links and Resources: Connect with Eddie Martucci on LinkedIn Visit Akili Season 1 Episode: Akili’s Revolutionary Digital Therapeutic with Eddie Martucci Co-Founder/CEO of Akili Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Let's face it, entrepreneurship is tough. While we're certainly seeing a much needed correction in the market this does not make it easier for any trailblazers out there. Sales cycles have slowed down. Decision making became even less transparent. And finally, funding became a numbers game. Now add to all of this, some recent bankruptcies and your head starts spinning. So what should a Digital Therapeutics entrepreneur do? Since we have the pleasure of hosting dozens upon dozens of leaders in the industry, we decided to put together a special episode with their advice to the awesome entrepreneurs out there. Guest Links and Resources: Connect with Acacia Parks on LinkedIn Visit Liquid Amber Connect with Ameya Phadke, Ph.D on LinkedIn Visit Chiesi Group Connect with Omar Manejwala, MD on LinkedIn Visit Dario Health Connect with Jennifer Goldsack on LinkedIn Visit Digital Medicine Society Connect with Benjamin Alouf, MD on LinkedIn Visit Limbix Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jennifer Goldsack, CEO of Digital Medicine Society (DiMe). In their own words, DiMe is a global non-profit and the professional home for all members of the digital medicine community. In this episode, we cover: The origin and mission of DiMe Defining digital health, digital medicine and digital therapeutics Collaborating with the Digital Therapeutics Alliance Stakeholder management for patients and pharma The payer contracting framework Working across the healthcare ecosystem DiMe's approach to the science behind digital medicine and digital measurement products Guest Links and Resources: Connect with Jennifer Goldsack on LinkedIn Visit dimesociety.org Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Joe Perekupka, CEO of Freespira. In their own words Freespira is 'the only medication-free, FDA-cleared digital therapeutic treatment proven to significantly reduce or eliminate symptoms of panic disorder, panic attacks and post-traumatic stress disorder in just 28 days.' In this episode, we cover: The founding story of Freespira The user experience from prescription to daily use The role of health coaches within Freespira Identifying potential candidates for Freespira The current landscape for panic disorder treatment and research into MDMA-assisted therapies Evidence generation to FDA approval journey Evolving pricing models The scope of PTSD across the US Guest Links and Resources: Connect with Joseph Perekupka on LinkedIn Visit freespira.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, Eugene sits down with Megan Coder, Chief Policy Officer of the Digital Therapeutics Alliance (DTA). Tune in to hear the exciting and positive advancements taking place in the digital therapeutics industry following the DTA Inaugural Summit. In this episode, we cover: The success of DTA's first summit in Washington DC Introducing a new definition of DTx The new DTx Evalution Toolkit Developing the new European DTx Policy Report in partnership with Healthware Guest Links and Resources: Connect with Megan Coder on LinkedIn Visit dtxalliance.org Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jenna Carl PhD, Chief Medical Officer at Big Health. Big Health belives in mental health care for all and that their digital therapeutics are safe and effective non-drug options for mental health. In this episode, we cover: Consumer Experience with Sleepio vs Daylight: Gain insights into the end consumer experience and how these solutions are designed to improve sleep and mental well-being. Go-to-Market Strategy: Explore Big Health's go-to-market strategy, and activating employers to reach upstream employees and achieve high engagement rates. Deep Dive into the Relationship with CVS: Gain a deeper understanding of Big Health's relationship with CVS, specifically regarding medication targeting. Abandoning Direct-to-Consumer (DTC): Uncover the reasons behind Big Health's decision to shift away from a direct-to-consumer approach and explore the implications of this strategic shift. Clinical Evidence and Decision-making Processes: Learn about Big Health's extensive clinical study basis and the rationale behind this approach. Future Product Pipeline: Gain insights into Big Health's future plans for additional products and the exciting developments in their pipeline. Big Health and Pear's Differing Go-To-Market Strategies: Explore the differing go-to-market routes between Big Health and Pear Therapeutics Stand-alone DTx vs. Disease Management 2.0: Understand the merits and challenges of stand-alone digital therapeutics versus disease management 2.0 Guest Links and Resources: Connect with Jenna Carl on LinkedIn Visit BigHealth.com Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Aaron Gani, Founder and CEO of BehaVR. BehaVR translates proven science into immersive and engaging XR therapeutics for mental and behavioral health. In this episode, we cover: Origin Story: Aaron Gani shares the origin story of BehaVR, starting from its inception in 2016 and the inspiration behind creating immersive XR therapeutics for mental and behavioral health. Funding Journey and Milestones: Walk through BehaVR's funding journey, uncovering the key milestones achieved with each funding round and how it has shaped the company's growth and impact in the digital therapeutics landscape. Patient Journey Using VR: Gain insights into the end customer experience offered by BehaVR, highlighting the effectiveness of immersive therapeutics in supporting mental well-being. Scientific Hypothesis and Evidence Generation: Explore the hypothesis that BehaVR is built upon and learn how their evidence generation journey is proving the effectiveness of their immersive XR therapeutics, showcasing the power of mind-body connections. Merging with OxfordVR and FDA Approval: Discover the decision-making process behind BehaVR's merger with OxfordVR and their journey towards FDA approval. Business Hypothesis and Scaling Plan: Delve into BehaVR's current business hypothesis and explore their scaling plan. Partnership with Sumitomo Dainippon: Aaron expands on BehaVR's partnership with Sumitomo Dainippon and discusses the commercial arrangement that led to this collaboration. Access to Care: Explore the accessibility of virtual reality therapy and its role in improving access to care for patients. Pear Therapeutics and the Future of PDTs: Aaron shares his thoughts on Pear Therapeutics and discusses the future of Prescription Digital Therapeutics (PDTs), providing insights into the evolving landscape of digital therapeutics and its potential to revolutionize mental health care. Guest Links and Resources: Connect with Aaron Gani on LinkedIn Visit BehaVR Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode of #DTxPodcast, Eugene Borukhovich sits down with Acacia Parks, Founder of Liquid Amber Consulting. Liquid Amber helps digital health and DTx companies support the claims they want to make using scientific evidence, in the ways that will be compelling to the audiences they care about. Topics include: A Day in the Life of a Chief Science Officer: Gain insights into the role of a Chief Science Officer before Acacia Parks ventured into her own entrepreneurial journey, and get a glimpse into the challenges and responsibilities involved in the position. Liquid Amber: Uncover the story behind the name "Liquid Amber" and explore the mission and vision of the company. Evidence Generation Process: Dive deep into the process of setting up the right processes and PDT vs non PDT. Active Ingredients in DTx: Discover how active ingredients play a crucial role in both molecular-based and software-based interventions. Pro Tips for Regulatory Approvals: Acacia Parks shares her expert advice on getting regulatory approvals for DTx. Learn what companies should do before, during, and right after the regulatory process to streamline the approval journey. Being a Patient on Freespira: Get a firsthand perspective as Acacia Parks walks us through her personal experience using Freespira. Guest Links and Resources: Connect with Acacia Parks on LinkedIn Visit liquidamber.consulting Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode Eugene Borukhovich sits down with Ameya Phadke, Ph.D., Patient Non-Pharma Solutions Leader at Chiesi Group. Join them as they delve into the world of digital therapeutics and explore how pharma companies are embracing digital health to revolutionize patient care. Topics include: The Chiesi Group's History: Discover the largest international pharmaceutical Group certified as a B Corp, with a rich history spanning over 80 years, and their focus on respiratory diseases, special care, and rare diseases. Pharma Moving into the Digital Health Space: Gain insights into how Chiesi Group recognized the need to go beyond medications to deliver impactful outcomes for patients, leading them to explore the digital therapeutics field. The Kaia Deal: Learn about Chiesi's partnership with Kaia and their shared vision to address the access gap in pulmonary rehabilitation through digital solutions, exemplifying the power of collaboration and building something impactful together. Standalone Digital Therapeutics vs. Disease Management: Understand the importance of both standalone digital therapeutics and disease management platforms in the patient journey, with each serving unique purposes and addressing different aspects of care. Chiesi's Partnership with Aptar: Explore Chiesi's collaboration with Aptar, aiming to make disease management practices more accessible to patients by bringing services to their fingertips, ultimately empowering patients and enhancing respiratory care. Challenges of Drug+: Reflect on the challenges and opportunities that arise when combining digital therapeutics with pharma, including the need to align the mechanism of action with desired outcomes and the importance of identifying viable use cases. The Future of DTx after Pear Therapeutics: Gain insights into the evolving digital therapeutics landscape and the enduring mission of Chiesi Group and other companies to leverage digital solutions to improve patient lives, regardless of market trends. Guest Links and Resources: Connect with Ameya Phadke on LinkedIn Visit www.chiesi.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jens Noertershaeuser, Founder & Co-CEO of Kranus Health. In their own words, Kranus Health’s mission is to revolutionize men's health by providing innovative and accessible healthcare solutions. As one of only 10 companies with a permanent approval, Kranus Edera is the only the first digital health app (DiGA) for the treatment of erectile dysfunction. In this episode, we cover: The background to Kranus Health The focus on men’s health and erectile dysfunction as a flagship product Products in development and the future of Kranus Health The funding journey Patient experience using the product Evidence generation and the DiGA process Insurance company reimbursment Guest Links and Resources: Connect with Jens Noertershaeuser on LinkedIn Visit kranushealth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Omar Manejwala, MD, Chief Medical Officer at DarioHealth. In their own words, DarioHealth makes it easy for people to care for their health, with continuous and connected support that anticipates needs, understands motivation, and simplifies behavior change to put better health and outcomes in everyone’s reach. In this episode, we cover: The history of DarioHealth DTx vs disease management The future of PDTs Patient/customer experience using DarioHealth The pipeline to adding different therapeutic areas Clinical differentiation from competitors Clinical trials and evidence generation DarioHealth's relationship with Sanofi Guest Links and Resources: Connect with Omar Manejwala on LinkedIn Visit dariohealth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Alberta Spreafico, Global Head of Digital Health & Innovation Strategy at Healthware Group. In their own words, Healthware combines advisory, agency services and technology capabilities to improve health outcomes while delivering transformational business results. In this episode, we cover: The background to Healthware VR Therapies with Orion Pharma Scaling challenges across the EU The DTx landscape in Italy Healthwares partnership with the Digital Therapeutics Alliance The future of PDT's Guest Links and Resources: Connect with Alberta Spreafico on LinkedIn Visit healthwaregroup.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jennifer Goldsack, CEO of Digital Medicine Society (DiMe). In their own words, DiMe is a global non-profit and the professional home for all members of the digital medicine community. In this episode, we cover: The origin and mission of DiMe Defining digital health, digital medicine and digital therapeutics Collaborating with the Digital Therapeutic Alliance Stakeholder management for patients and pharma The payer contracting framework Working across the healthcare ecosystem DiMe's approach to the science behind digital medicine and digital measurement products Guest Links and Resources: Connect with Jennifer Goldsack on LinkedIn Visit dimesociety.org Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Benjamin Alouf, Chief Medical Officer at Limbix. In their own words, Limbix is the first digital therapeutic for adolescent depression. In this episode, we cover: Origin of the company and story behind the name 'Limbix' The funding journey and key milestones achieved The choice to focus on the young adult population in particular Patient experience with SparkRx Defining good patient engagement in adolescent mental health Evidence generation and FDA submission process Business hypthothesis and scaling plan The future of the PDT market Guest Links and Resources: Connect with Benjamin Alouf on LinkedIn Visit Limbix.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Andrzej Jończyk, MD, Co-founder and CEO USA of Prosoma. In their own words, Prosoma develops a portfolio of digital therapeutic medical software products that cover the entirety of behavioral treatment needs of cancer patients. In this episode, we cover: The background to Prosoma The funding journey and milestones reached Patient experience using Prosomo's Living Well product How Living Well is personalized specifically for women living with cancer Evidence generation and journey to PDT & DiGA Engagement levels in the technology Commercial traction across Europe and expansion into the USA Guest Links and Resources: Connect with Andrzej Jończyk, MD on LinkedIn Visit Prosoma.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jason Kahn, Co-founder and Chief Science Officer at Mightier. Mightier, in their own words, is a digital program for kids that uses their heart rate to teach coping skills through game-based play. In this episode, we cover: The founding story and meaning behind the name 'Mightier' Funding journey and key milestones in bringing the product to market Child and parent experience using Mightier The total addressable market for DTx in pediatric behavioral health The mechanism of action and the underlying technology utilized in Mightier Working with gaming companies Evidence generation and RCTS PDT's vs DTC's Guest Links and Resources: Connect with Jason Kahn on LinkedIn Visit Mightier Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we hear from Simon Levy, CEO and Co-founder, and Ann Montgomery, Chief Product Officer at Mahana. In their own words, Mahana develops digital treatments for people living with chronic health conditions, and their first treatment, Mahana for IBS, is now available as an FDA-cleared app. In this episode, we cover: The founding story and funding journey of Mahana Complexities of the end to end patient experience The freemium model and how that translates into a PDT Evidence generation and FDA clearance process Scaling plans for PDTs Guest Links and Resources: Connect with Simon Levy on LinkedIn Connect with Ann Montgomery on LinkedIn Visit Mahana.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this special episode of DTx Podcast, Eugene is joined by Brent Vaughan, CEO of Cognito, as well as industry leaders from previous episodes, to weigh in on the recent Pear Therapeutics news and the future of prescription digital therapeutics. In this episode, we cover: The impact on the PDT market Future efforts to move DME to PDT The impact on the entrepreneurs currently developing PDT’s Predictions on the future of Pear Therapeutics Reflections on the history and future of DTx from Chris Bergstrom (Amalgam RX), David Klein (Click Therapeutics), Andy Molnar (DTA), Sammeli Liikkanen (Orion), Francesca Wuttke (nen), Andrzej Jonczyk (Prosoma), Steve Driver (Advocate Health) and Grady Hannah (NightWare) Join the HealthXL platform for free today and be the first to read their analysis of Pear’s predicament and what it means for the DTx industry: https://portal-beta.healthxl.com/?s=2fb5 Guest Links and Resources: Connect with Brent Vaughan on LinkedIn Connect with Chris Bergstrom on LinkedIn Connect with David Klein on LinkedIn Connect with Andy Molnar on LinkedIn Connect with Sammeli Liikkanen on LinkedIn Connect with Francesca Wuttke on LinkedIn Connect with Andrzej Jonczyk on LinkedIn Connect with Steve Driver on LinkedIn Connect with Grady Hannah on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Josh Sackman, President and Co-founder of AppliedVR. AppliedVR, in their own words, provide virtual reality-based treatments that represent a comprehensive approach to chronic pain that empowers patients with accessible digital tools self-managed in their own home. In this episode, we cover: The origin story of AppliedVR Transitioning from an app store for health VR to focus pain management market Patient experience and the pain management pipeline Funding journey and key funding milestones The scientific hypothesis of "mind over matter" behind AppliedVR's approach and evidence generation journey The FDA approval process for AppliedVR and lessons learned for entrepreneurs. AppliedVR's current business hypothesis and scaling plan Market channels and scaling VR Guest Links and Resources: Connect with Josh Sackman on LinkedIn Visit www.appliedvr.io Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Jo Masterson, CEO and Co-Founder of 2Morrow. In their own words 2Morrow's mission is to help millions improve their lives with the use of evidence-based, behavioral change programs. In this episode, we cover: The founding philosophy of 2Morrow and co-founding a company with your partner The funding journey The NIH grant for 2Morrow's program for pain Using a DTx to cope with pain that will not be effected by behaviour change Consumer experience using different 2Morrow programs Core principles of acceptance, awareness and mindfulness Evidence generation and approach to market Guest Links and Resources: Connect with Jo Masterson on LinkedIn Visit www.2morrowinc.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Brian Wallace, CMO and Co-Founder of Calmsie. Calmsie in their own words are empowering children to develop emotional resilience from an early age. Calmsie creates engaging DTx video games designed to improve outcomes for children with depression and anxiety. In this episode, we cover: Translating addiction science to treat depression and anxiety in children The origin story and funding journey to Calmsie Parent and child experiences using the gamified program Emotional resilience training for prevention of mental health issues How the Calmsie video game affects the brain Evidence generation and deciding on PDT vs non-PDT routes The free workbook helping children understand the war in Ukraine Guest Links and Resources: Connect with Brian Wallace on LinkedIn Visit calmsie.ai Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Sylvain Piquet, COO and Co-founder of Five Lives, the app that leverages the new science of brain aging, neuroplasticity, and cognitive reserve to help people improve their brain health and prevent cognitive decline and dementia. In this episode, we cover: The origin story of Five Lives and the motivation behind focusing on dementia and cognitive decline. The demographics benefitting from using Five Lives Gamifying behaviour change Evidence generation and funding journey The advantages of direct-to-consumer distribution through the app store How digital therapeutics can fit within the NHS The challenges of implementing DTx across UK, French, and German markets Guest Links and Resources: Connect with Sylvain Piquet on LinkedIn Visit www.fivelives.health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Hannes Klöpper, CEO of HelloBetter. HelloBetter, in their own words, wants to empower as many people as possible to manage their own mental health and improve their quality of life – anywhere and at any time, without the wait lists. In this episode, we cover: The origin story of HelloBetter, from university research to becoming a digital therapeutic. Structuring a DTx into accessible and consumable courses The patient journey, from receiving a prescription to activating and using the platform. The DiGA process: evidence, benefits and commercialization The reaction of EU vs US investors Guest Links and Resources: Connect with Hannes Klöpper on LinkedIn Visit hellobetter.de Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health | Orion Pharma Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Joe Perekupka, CEO of Freespira. In their own words Freespira is 'the only medication-free, FDA-cleared digital therapeutic treatment proven to significantly reduce or eliminate symptoms of panic disorder, panic attacks and post-traumatic stress disorder in just 28 days.' In this episode, we cover: The founding story of Freespira The user experience from prescription to daily use The role of health coaches within Freespira Identifying potential candidates for Freespira The current landscape for panic disorder treatment and research into MDMA-assisted therapies Evidence generation to FDA approval journey Evolving pricing models The scope of PTSD across the US Guest Links and Resources: Connect with Joseph Perekupka on LinkedIn Visit freespira.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Ali Hashemi, Co-founder of meta[bolic]. In their own words, meta[bolic] is a hybrid digital therapeutics company focused on addressing the global metabolic health crisis. In this episode, we cover: The initial business hypothesis of GluCare and meta[bolic] Digital therapeutics vs disease management Why we are becoming more metabolically unstable than previous generations The global metabolic problem Patient experience on the meta[bolic] platform Guest Links and Resources: Connect with Ali Hashemi on LinkedIn Visit Glucare.Health Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we kick off the next chapter of the DTx podcast. We heard you loud and clear - this industry is here to stay and therefore we are moving away from Seasons and going Evergreen - so what does that mean for you? It means we will continue bringing you deep conversations and knowledge from trailblazers, policy makers, associations and of course patients and health consumers. Chandana Fitzgerald, CEO of HealthXL has agreed to continue being my partner on this podcast asking the tough questions and dive into a short recap of last year’s DTx news but also what we are seeing as some of the key trends emerging into 2023 and beyond.   In this episode, we cover: How digital therapeutics have evolved and the future of DTx The Access to Prescription Digital Therapeutics Act of 2022  Digital Therapeutic Alliance approaches to evidence generation and upcoming conferences  Scaling DTx Pharmacy Benefits Management systems Navigating Sick care vs Healthcare And much more! Guest Links and Resources: Chandana Fitzgerald on LinkedIn Visit HealthXL Host Links: Eugene Borukhovich: Twitter | LinkedIn Chandana Fitzgerald, MD: Twitter | LinkedIn YourCoach.health: Website | Twitter Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Health Today and the DTx Podcast would not be possible without the support of leading organizations. Thank you to: • Presenting Partner: Amalgam Rx • Sponsors: Akili • Big Health • Click Therapeutics • Lindus Health Follow Digital Health Today: Browse Episodes • Twitter • LinkedIn • Facebook • Instagram Follow Health Podcast Network: Browse Shows • LinkedIn • Twitter • Facebook • Instagram

In this episode, we hear from Louisa Stuwe & Aymeric Perchant, eHealth projects directors at the French Ministry of Health. For those who follow this podcast and the digital therapeutics industry, you know that all eyes have been on Germany with the DiGA. Well by popular demand, I have the pleasure of hosting Louisa and Aymeric to give YOU, our audience, a bit of history and the current state of digital therapeutics in France. In this episode, we cover: The digital health journey at the Ministry of Health DTx Reinbursement and Evidence Generation Physician education and adoption Lessons learned from Germany and DiGA The role of doctors, nurse & pharmacists in prescription DTx Guest Links and Resources: Connect with Louisa Stüwe on LinkedIn Connect with Aymeric Perchant on LinkedIn HTA Agency: https://www.has-sante.fr/ National Digital Health Agency : https://esante.gouv.fr/ Convergence platform: File document for interop & security certification + GDPR : https://convergence.esante.gouv.fr/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Shailja Dixit, CEO of Curio. In their own words: 'Curio is a Digital Therapeutics company with tailor-made Cognitive Behavioral Therapy programs for Women across the cycle of life – encompassing age groups, physiological conditions and social settings'. Topics include: The Founding Story of Curio Using Digital to Destigmatize Mental Health Support User experience of the MamaLift product Combining methods of Cognitive Behavioural Therapy, Interpersonal Therapy and Behavioural Activation Therapy  PDT vs Physician recommended DTx  Guest Links and Resources: Connect with Shailja Dixit on LinkedIn Visit https://www.curiodigitaltx.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Dominik Burziwoda, CEO and Co-Founder of Perfood. Perfood, in their own words is working on a pipeline of 'prescription digital therapeutics powered by personalized nutrition'. In this episode, we cover: The background and creation of Perfood The digital health scene in Germany Consumer experience of Perfood The process of DiGA approval and commercialisation Guest Links and Resources: Connect with Dominik Burziwoda on LinkedIn Visit https://perfood.de/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Clara Campàs, Managing Partner and Co-Founder at Asabys Partners. Asabys Partners is an venture fund based in Barcelona, Spain investing in healthcare and life sciences innovation. In this episode, we cover: The healthcare thesis at Asabys Ventures Stand-alone DTx (biotech-like pipelines) vs. Drug+ DTx + Approaching valuations and investments when entering the DTx space Drivers for new capital injections in DTx in the last 2 years Scaling digital therapeutics in Europe Guest Links and Resources: Connect with Clara Campàs on LinkedIn Visit https://asabys.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this coffee talk with AmalgamRX we dive into the challenges being faced by health systems as they work to assess, develop, and implement solutions at the time of a clinical decision. We'll explore the major pain points that keep projects from reaching their full potential, what it takes to overcome these challenges and what you can do when you're developing a digital therapeutic solution for your organization. There's also some tips that apply to payers and pharma as they play a key role in the successful development and implementation of digital therapies. Guest Links and Resources: Connect with Jenni Main on LinkedIn Connect with Dr. Suzanne Clough on LinkedIn Visit https://amalgamrx.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Sammeli Liikkanen, Digital Medicines Director at Orion Corporation. Orion Pharma is a globally operating Finnish pharmaceutical company with core therapy areas of neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases. In this episode, we cover: How Orion approaches non-molecular innovation Solving misconceptions in digital medicine VR as a modality for DTx Patient experience using VR Approaches to evidence generation Commercializing stand alone DTx vs Drug+ Guest Links and Resources: Connect with Sammeli Liikkanen on LinkedIn Visit https://www.orion.fi/en/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we hear from Sai Shankar, President of the Digital Health Unit at Aptar Pharma. Aptar Pharma provides drug delivery systems, active material science solutions and services globally- some products include: nasal spray pumps, MDI valves, dose indicators & counters, DPIs, electronic / connected devices, eye-droppers, elastomeric components (for injectable delivery devices), and more! In this episode, we cover: The background to AptarGroup, Aptar Pharma and its acquisition of Voluntis How the Aptar digital health unit came about Rationale behind the acquisition of Cohero Health Bringing together teams and lessons learned in integration processes Drug+ and key go-to-market opportunities Evidence generation and life sciences partner What is next for the digital health unit at Aptar Pharma? Guest Links and Resources: Connect with Sai Shankar on LinkedIn Visit: https://www.aptar.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Francesca Wuttke, Founder and CEO of Nen who is focusing on building prescription digital therapeutic at a cross-section of pediatrics, pain with an initial focus in oncology. In this episode, we cover: The background to nen and naming the company Gamifying CBT for treating children's pain Targeting the psychological aspects of pain Treating unmet needs in oncology Patient and parent experience Clinical evidence generation and PDT Business hypothesis, market entry, pricing and reimbursements Guest Links and Resources: Connect with Francesca Wuttke on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode I speak with Seth Feuerstein, Founder and CEO of Oui therapeutics, a digital therapeutic company that recently came out of stealth. In their own words: Oui is purpose built to tackle suicide and other challenging health care problems. In this episode, we cover: The background and funding journey to creating Oui What are the existing options for suicide prevention? What is the patient experience on a digital therapeutic for suicide? Approaching to the FDA with a DTx for suicide prevention Commercializing DTx and scaling the company Guest Links and Resources: Connect with Seth Feuerstein on LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Nate Beyor, managing director and partner of BCG healthcare. We dive into many topics around digital therapeutics and get a bird's eye view across BCG's customer base. In this episode, we cover: New company creation: large company spin-outs vs entrepreneurs  What it takes to build a team that can take a digital therapeutic to market Why build rather than buy a new DTx Approaching medical pharma clients vs approaching smaller DTx companies Go to market strategy and value creation: Standalone vs Drug+ Embedding clinical decision support into workflows Guest Links and Resources: Connect with Nate Beyor on: LinkedIn Visit: www.bcg.com/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Meg Barron, Vice President of Digital Health Strategy at the American Medical Association, which represents the voices of over ¼ million physicians and is the largest and only national association that convenes 190+ state and specialty medical societies and other critical stakeholders In this episode, we cover: AMA’s position on digital health- how do we help to make technology an asset to physicians and patients  How the AMA Physician Innovation Network is connecting healthtech companies and physicians Patient experience on digital therapies and addressing physician burnout Expectations and reimbursement of the physician and the return on health value framework And much more! Guest Links and Resources: Connect with Meg Barron on LinkedIn Visit www.ama-assn.org Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Today, I speak with Mark Bini, Vice President of Pharmacy Care Solutions at Evernorth - Cigna’s health services arm which spearheaded a digital health formulary which includes companies such as Omada, QuitGenious and Hinge Health  In this episode, we cover: The history and evolution of Evernorth How Evernorth works with it's parent Cigna colleagues What it takes for a DTx to be part of the formulary The patient experience using DTx How Evernorth set the pricing with each DTx partner and how to “activate” upstream with clients When will Evernorth include PDT's? and much more! Guest Links and Resources: Connect with Mark Bini on LinkedIn Visit www.evernorth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we hear from Steve Driver, the Medical Director of Digital Therapeutics at one of the largest health systems in the US, Advocate Aurora Health. I have been itching to get a view from a health system perspective on this show since season one. As a practicing cardiologist, it is always great to hear from somebody who is practicing this in the front lines.  We cover:  The expectations of the role as a Medical Director of Digital Therapeutics for a large health system. The level of evidence required for adoption in a health system The future of the patient journey using DTx DTx standalone versus drug+ The role of the pharmacists in dispensing digital therapeutics Guest Links and Resources: Connect with Steve Driver on LinkedIn | Twitter Visit www.advocateaurorahealth.org/ Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we jumped right into the drug+ discussion with Pamela Stahl, Chief Commercial Officer at Sidekick Health. In their own words Sidekick health is all about “Gamified digital therapeutics built on science, rooted in behavioral economics, and scalable across multiple therapeutic areas.” In this episode, we cover: The origin of Sidekick Health and what led Tryggvi to start the company The funding journey from being a young company in Iceland to today Patient and health consumer experience Combining clinical evidence with gamification The complexities of clinical trials with pharma clients And much more! Guest Links and Resources: Connect with Pamela Stahl on LinkedIn Visit sidekickhealth.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode we jump back into interviewing some of the early trailblazers and speak with Dennis Wall, Founder of Cognoa. In their owns words, “Cognoa is a pediatric behavioral health company developing digital diagnostic and therapeutic products with the goals of enabling earlier and more equitable access to care and improving the lives and outcomes of children and families living with behavioral health conditions, starting with autism.” In this episode, we cover: The founding story and funding journey of Cognoa Patient journey for children using Canvas Dx for autism spectrum disorder (ASD) diagnostic and therapeutics How the diagnosis and treatment interplay works in the context of a autism digital therapeutic Evidence generation journey Working flexibly with pediatricians and doctors for distribution The collaborative care model alongside DTx Guest Links and Resources: Connect with Dennis Wall on LinkedIn | Twitter Visit: cognoa.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we take a break from interviewing entrepreneurs and switch gears to get into a head of one of the investors in the industry, Justin Norden. Justin is a Partner at GSR Ventures where he focuses on early-stage investments in digital health. Prior to GSR Ventures, he was CEO and co-founder of Trustworthy AI which was acquired by Waymo (Google self-driving). He worked on the healthcare team at Apple, co-founded Indicator (an NLP based platform for biopharma decision making), and helped start the Stanford Center for Digital Health. In this episode, we cover: The Healthcare Thesis at GSR Ventures Virtual Reality (VR) Digital Therapeutics Stand-alone DTx (biotech-like pipelines) vs. Drug+ DTx What it would take to scale existing Prescription Digital Therapeutics The Role Of Health Coaching alongside AI automation The Drivers of Success Going Forward for the Digital Therapeutics Market Guest Links and Resources: Connect with Justin Norden on LinkedIn | Twitter Visit https://gsrventuresglobal.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Gut-directed hypnotherapy has an ability to retrain both nervous systems to work together to communicate better, giving the central nervous system the ability to downregulate the hyper vigilant signals that are being sent up from the enteric nervous system. Despite there being over 20 different randomized controlled trials showing that gut directed hypnotherapy has a positive impact on all of the symptoms of for functional GI disorders, experts still don't really know exactly why it works To learn more about the future of gut-directed hypnotherapy and the role DTx can play, I went straight to Tim Rudolphi, CEO of metaMe Health. metaMe, in their own words “believe the best medicine may not be medicine at all. By developing innovative prescription digital therapeutics (PDTs) to combat many common chronic conditions, they are putting the power to heal right in the hands of their patients.” starting with gut health. In this episode, we cover: The founding story of metaMe Health The scientific thesis behind gut-directed hypnotherapy metaMe’s business hypothesis in action: the process of selling prescription digital therapeutic to a doctor Commercialization of Prescription Digital Therapeutics Making space for DTx alongside health coaching Guest Links and Resources: Connect with Tim Rudolphi on LinkedIn | Twitter Visit: metamehealth.com Episode Mentions: Danny Bern Brian Dolan The Lancet Mahana Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Biofourmis is not your typical standalone DTx company! On the heels of a $300M round, Biofourmis has evolved to a full data driven healthcare services organization with a strong foundation of digital therapies driving care decisions. To learn more about their work and plans for the future, I went straight to Kuldeep Singh Rajput, founder and CEO of Biofourmis. Biofourmis, in their own words, “utilizes machine learning, integrated technology and an FDA-cleared analytics engine to streamline connections between patients and care teams, leading to better outcomes for all.” In this episode we cover: The path from creation to funding Digital therapeutic companies evolving into virtual care platforms Kuldeep’s business hypothesis to entrepreneurial journey Being device agnostic: build vs buy Patient adoption and utilization And much more! Guest Links and Resources: Connect with Kuldeep Singh on LinkedIn | Twitter Visit biofourmis.com Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Cognitive behavioral therapy (CBT) is an evidence-based form of therapy that has been in use for decades. My guest in this episode believes that CBT can be applied to create better therapeutics, and, in fact, that's exactly what his company is called: Better Therapeutics. Dr. Mark Berman, the Chief Medical Officer at Better Therapeutics, explained that the goal of CBT is to "help people change some of those core beliefs, which then directly influence what we do on a day to day basis." And while CBT was originally applied to help people with conditions like PTSD, anxiety and depression, the team at Better Therapeutics have developed their own variant of CBT to apply the core principles of CBT to the ideas that drive root behaviors like diet, exercise and other supportive lifestyle behaviors. Tune into this episode to hear how Better Therapeutics are creating new digital treatments to reverse the progression of cardiometabolic disease, improve quality of life and inform clinical decisions. In this episode, we cover: Patient experience using digital therapeutics for type 2 diabetes Nutritional CBT - Better Therapeutics innovative new form of Cognitive Behavioral Therapy Why companies are opting to create Prescription Digital Therapies rather than self-managed lifestyle apps What’s next in the Better Therapeutics pipeline and how these decisions are made The future of Digital Therapeutic infrastructure Guest Links and Resources: Connect with Mark Berman on LinkedIn | Twitter Visit bettertx.com Episode Mentions: Kevin Appelbaum - founder of Better TX: LinkedIn Margaret Moore - Founder & CEO Wellcoaches Corporation: LinkedIn Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Everyone knows it's important to get a good night's sleep, but what if nightmares are keeping you aware? Frequent nightmares can disrupt your sleep, cause stress and interfere with your ability to function during the day. A diagnosis of "nightmare disorder" can occur if disturbing dreams cause stress and keep someone from getting enough sleep.(1) This episode features Grady Hannah, co-founder and CEO of NightWare, the company behind an innovative prescription digital therapeutic that alleviates the effects of traumatic nightmares most often associated with PTSD. Through software on an Apple Watch, NightWare monitors a persons' sleep patterns, and uses machine learning to identify a patients' nightmares and intervene in them. Once a nightmare is detected, NightWare can activate the watch to wake the sleeper out of traumatic nightmares, but without actually waking them out of sleep. In this episode, we cover: The problem and solution that led to developing a DTx for Apple Watch The types of trauma that can lead to Nightmare Disorder or nightmares from PTSD Evidence generation required to support FDA "Breakthrough Status" in 2020 How to reach out and educate prescribers Guest Links and Resources: Connect with Grady Hannah on LinkedIn Visit NightWare on the Web Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram (1) Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/nightmare-disorder/diagnosis-treatment/drc-20353520

The association between music and medicine has been discussed for decades, and the development of music therapy has been shown to improve outcomes for patients of all ages, and from the immune system to the mind. To tell us more about how music can play a role in digital therapeutics, we hear from Brian Harris, the Co-founder and CEO of MedRhythms. MedRhythms is a digital therapeutics company focused on the intersection music, neuroscience and technology. They understand that millions of people live with persistent walking deficits due to injury or disease, and, to address the needs of this patient population, MedRhythms is building the world's first prescription music platform. Thanks to MedRhythms' partnership with Universal Music Group, they provide patients with therapy via music that they know and enjoy. This enables their digital therapeutics to use music content that is curated and screened via a patented process, which carefully selects and customizes interventions to each user. Tune in for an interesting discussion that will make you want to sit up and hear the music! Topics covered: The genesis of MedRhythms - why it all started and going from hospital to home. How music can be used to improve walking following neurologic disease and injury  Evidence generation and how it is evolving Why MedRhythms decided to go the route of a PDT (Prescription Digital Therapeutic) rather than a consumer route Let's talk DTx business: what was the MedRythms original business hypothesis, and how did it change over time? Can you talk about pricing at all?  If you were to dissect your deal with Biogen, what is your business hypothesis on how this partnership will make you both money ? MedRhythms partnership with Universal Music Group, and what it means to users and much more! Guest Links and Resources: Connect with Brian Harris on LinkedIn | Twitter Visit MedRhythms, Inc. Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Join me for this conversation with M. Jason Brooke, MSE, JD, CSQE, Attorney and Managing Member of Brooke Consulting LLC. Brooke Consulting is a digital health legal and regulatory advisory firm. Jason offers a unique, multi-disciplinary perspective on the digital health industry as a regulatory attorney, scientist, technologist, and quality consultant. Jason and I talk about the three main pathways through the FDA: the 510(k) process, De Novo process and PMA (Premarket approval) process. We discuss the pros and cons of each pathway, and the requirements for testing and clinical data. Jason also explains the types of different types of testing such as verification and validation (bench top) testing, non-clinical animal testing, and clinical testing. But what about cybersecurity and biocompatibility which may be required for some SaMD (Software as a Medical Device) and sensors used in DTx solutions? Yes, Jason shares some insights on that as well! In this episode, we cover: Key milestones over the past 10 years for the DTx industry from a regulatory perspective Pros and cons of pursuing one of the three main pathways for FDA approval for a DTx Jason's opinion about what is currently missing with DTx SaMD regulation to uphold it to the same standard as a medical device Comparisons of the regulatory developments in the US to other areas of the world (EU, APAC) The future of regulatory frameworks for DTx Predictions and suggestions for regulators as the DTx industry moves forward Guest Links and Resources: Connect with Jason Brooke on LinkedIn FDA Information about Sofware as a Medical Device (SaMD) Visit Brooke Consulting's website About Jason: Jason Brooke brings a focused expertise in the medical device industry that combines nearly 20 years of experience ranging from science and technology design, development, implementation, and testing; to business strategy and operations; to legal and regulatory compliance. Jason has conducted scientific research (pre-clinical and clinical) and technology development in academic and industry environments as a biomedical engineer, worked within the FDA’s Center for Devices and Radiological Health as a regulatory affairs program analyst, counseled clients as an attorney and consultant focused on the medical device and digital health space, and served as the chief executive officer, general counsel, and vice-president of regulatory and quality for small medical device companies.  Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Mike Pace, Founder & CEO of PalmHealthco. PalmHealthco provides market access, commercialization, evidence generation and go-to-market executive advisory and strategic consulting services to digital health, biopharmaceutical and medical device firms around the world.  Mike and I talk about the differences in going to market and the commercial pathways for biopharmaceuticals compared to PDTs. Mike talks about what we are seeing in the marketplace with some of the early PDT trailblazers and the opportunity within the industry that exists for patient centric and value-based care. We discuss the conundrum of pricing PDTs, what other countries are leading the way in the industry… and more! In this episode, we cover: The work and progress we've seen in the marketplace with some of the early trailblazers and leaders Should the DTx industry continue to pursue claims-based reimbursement, or would it be better to jump straight to value-based reimbursement? What is the incremental benefit a digital therapeutic product gains in payment or reimbursement dollars by just labeling itself as a digital therapeutic versus not doing so? How do we build the adoption flywheel for DTx and not have price become an obstacle? Guest Links and Resources: Connect with Mike Pace on LinkedIn | Twitter Learn more about PalmHealthCo Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Timothy Aungst, a clinician, academic, public speaker, writer and, of course, pharmacist. In 2016, Tim founded The Digital Apothecary as a blog specifically for pharmacists to provide news and resources related to digital health topics and interests. Tim is also an advisor at HealthXL, a Clinical Writer for GoodRx, a member of the Digital Therapeutics Alliance Healthcare Provider Advisory Group, and an Associate Professor of Pharmacy Practice at Massachusetts College of Pharmacy and Health Sciences. In this episode, we cover: The role of the Pharmacist as it relates to DTx How do we compare Prescription Digital Therapeutics (PDT) versus traditional standards of care? How are DTx dispensed? And how do pharmacists at the front lines feel about DTx? Do pharmacy services need to be redesigned in the context of DTx? Do DTx have drug interactions? How do we train current and future learners about DTx and the digitization of healthcare? Guest Links and Resources: Connect with Timothy Aungst, PharmD on LinkedIn | Twitter Visit The Digital Apothecary Episode Mentions: Megan Coder Risa Vatanka APhA - Annual Meeting and DigitalHealth.Rx Digital Therapeutics Alliance Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we hear from Andy Molnar, CEO at the Digital Therapeutics Alliance. Andy dives into what they are working on to propel the DTx industry forward, and the international scope of his work in Europe, Asia Pacific and beyond. We also discuss the recent trends with commercial payers and reimbursements - or lack thereof - and much more. Key Takeaway: Be sure to check out the link to the DTx Value Assessment and Integration Guide put together by the DTx Alliance. It is designed to support healthcare decision makers as they assess and integrate DTx products into clinical use settings.  Guest Links and Resources: Learn more about Digital Therapeutics Alliance | Twitter | LinkedIn Connect with Andy Molnar Download the DTx Value Assessment & Integration Guide Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

We’ve got a very special guest on this episode. In Season 2 of DTx Podcast, we will focus greater attention on the evidence and commercialization of Digital Therapeutics. To bring even more context and insights to these conversations, I'm excited to introduce my partner this season: Dr. Chandana Fitzgerald, or as you’ll hear her own name of choice - "Dr No Craic"! Don't worry, the name will be explained in this episode. Join us as we briefly rewind the past year in DTx as we discuss SPAC’s and going public, new entrants and exits in the DTx space, and much more. Chandana also asks me a few questions about the history and goal of the DTx Podcast and what we have to look forward to in season two. But before we dive in… I remember when Martin Kelly introduced me to Chandana at one of the HealthXL events about 5 years ago. Chandana was witty, sharp and fun to speak with. Chandana comes from a clinical background as a physician, and is now the Chief Medical Officer and General Manager of HealthXL. And, as you'll here in this first episode of Season 2 of DTx Podcast, she's also my clinical and commercialization partner with all the tough questions for our guests!  Links and Resources: Brian Dolan Martin Kelly Ed Cox Dan Kendall Better Therapeutics Pear Therapeutics Akili Interactive Pierre Leurent Cognito Therapeutics Digital Therapeutics Alliance Mark Sluijs Alex Therapeutics Karuna Labs Nightware Smiley Scope Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

In this episode, we officially announce that the Digital Therapeutics Podcast is back for Season 2!  And the good news keeps coming as Eugene Borukhovich resumes his role as the talented host of the series! Eugene is a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the COO and co-founder at YourCoach.Health, the leading health coaching ecosystem working to deliver the power of health coaching to the world’s population.  Eugene is using his voice to make some noise about the exciting things happening in healthcare and specifically in Digital Therapeutics. Tune in as we share the success to date, what caused him to resume his hosting duties, and what's in store for Season 2! Links: Season 1, Episode 13 with Chris Bergstrom April Fool's Post: A DTx to Overcome Podcast Hesitancy Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App Season 2 of Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Sponsors: Akili | Big Health | Click Therapeutics | Lindus Health

In this final episode of Digital Therapeutics Edition, Eugene and his journalistic partner, Brian Dolan, reflect on the lessons learned, guest experts, and inspiring stories featured in season one. Brian is a journalist and the founder and lead writer of Exits & Outcomes, and in each episode, he asked the guests a pointed and challenging question about their digital solutions or their outlook on the DTx industry.  It's been an eventful five months, Brian says -- companies have been bought, merged, and sold, and have raised impressive rounds of funding -- but there are other areas that have seen little progress since the podcast was launched. There may be a season 2 of Digital Therapeutics Edition, but in the meantime, head over to healthxl.com/dtx to continue the conversation with Eugene and other experts. What do you think the future of DTx will look like?  >>Click here to read the transcript Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Abhishek Shah, the CEO and founder of Wellthy Therapeutics, is driven by the challenge of improving care delivery and outcomes for serious or chronic diseases like hypertension, type 2 diabetes, and kidney disease. Abhishek decided to start Wellthy after a successful career as an investor; he was inspired by the incredible ideas of other entrepreneurs, and tired of sitting on the sidelines, decided to build something himself.  Eugene and Abhishek talked back in December, and in that time, Wellthy has laid the groundwork for expansion throughout Asia Pacific and Europe. Eugene and Abhishek talk about his efforts to get investors to back Wellthy, the technology and regulatory landscape for DTx in South Asia, and whether Wellthy is facing competition from other industry players like Apollo during the COVID-19 pandemic. >>Click here to read the transcript Guest Links and Resources: Connect with Abhishek Shah: LinkedIn | Twitter Visit Wellthy Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Edward Kliphuis says his love for investing in digital health comes from his love of "playing with toys" and imagining the possible benefit to health outcomes if "damn cool" solutions are scaled significantly.  M Ventures backs many impressive companies-- like BioLink, Sonde Health, and Akili. In this episode, Ed talks to Eugene about M Ventures' founding philosophy (how to cut delayed feedback cycles, which M Ventures views as the biggest threat to humanity), approach to investing, and discusses some of the drivers of capital injections in the DTx space. Also, Ed offers his insight into what makes for a truly successful DTx company. >>Click here to read the transcript Guest Links and Resources: Connect with Edward Kliphuis: LinkedIn Visit Amadeus Capital Partners: Twitter | LinkedIn | Website Visit M Ventures: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Will Gibbs came to Octopus Ventures via a circuitous route - which interestingly, included setting up a rare breed pig farm in his native Essex. He landed in venture capital because he loves to build things - especially large-scale solutions for "taboo" or overlooked medical conditions like substance addiction, menopause, and acne.  Will and Eugene peek underneath the hood of venture capital. They discuss Octopus Ventures' investments in companies like Big Health and Quit Genius, the ins and outs of investing in DTx solutions, whether there is a valuation bubble in the DTx space, and Will offers some advice for startups looking to raise funds. >>Click here to read the transcript Viewing in Apple Podcasts? Visit our website for links to everything below: https://digitalhealthtoday.com/dtx/ Guest Links and Resources: Connect with Will Gibbs: LinkedIn https://linkedin.com/in/willgibbs1/ Visit Octopus Ventures: Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Ciara Clancy remembers the exact moment she decided to found Beats Medical; it was when she realized her Parkinson’s patient was 20 minutes late for metronome therapy because he was frozen at the door of the hospital, unable to take a single step. The metronome therapy, which helps Parkinson’s patients with their walking and movement, was only available in hospitals and via prescription. So Ciara decided to bring the therapy to them. Beats Medical turns a Parkinson’s patient’s phone into a medical device that gives live, visual feedback to help improve fine motor and gross motor skills, speech, and psychological well-being. Beats’ core technology has also been repurposed and deployed for other central nervous system (CNS) disorders and to help children cope with stress during the COVID-19 pandemic. Eugene and Ciara talk about some exciting recent developments in Beats’ product line, the evolution of their B2C and B2B models, and how Beats’ users have consistently driven the company to create better and more effective interventions. >>Click here to read the transcript Guest Links and Resources: Connect with Ciara Clancy: LinkedIn | Twitter Visit Beats Medical Ltd: Twitter | LinkedIn | YouTube| Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

As a former IBS sufferer, Elena Mustatea knows all too well that our standard model of healthcare does not adequately treat or support people with chronic conditions—especially digestive conditions. Elena eventually took matters into her own hands and attended a detox retreat in Thailand, which restored her physical and mental well-being and gave her the idea to start Bold Health. Bold Health is clinically validated and science-backed, and relieves the painful, life-disrupting symptoms of chronic digestive conditions through cognitive behavioral therapy and relaxation exercises. This intervention is crucial, because as Elena points out, 75% of the population suffers from GI symptoms in any given week, and 30% of the population has a diagnosable, long-term digestive condition. Digestive and autoimmune conditions are an enormous mental health burden and disproportionately affect women. Eugene and Elena talk about Elena’s journey from consulting and venture capital to digital therapeutics, Bold Health’s recent RCT results, and Elena’s view on how digital therapeutics and pharma could work together in the future. >>Click here to read the transcript Guest Links and Resources: Connect with Elena Mustatea: LinkedIn | Twitter Visit Bold Health: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Jonas Duss came to digital therapeutics from a mechanical and chemical engineering background. He landed at Kaia Health after he and his business partner, David Boutellier, realized they all shared a similar mission; to make proven, effective therapies for debilitating chronic conditions more widely accessible through digital platforms. Kaia Health offers people with musculoskeletal conditions virtual physical therapy sessions, complete with a health coach who helps motivate users to stay on track. In this episode, Jonas tells Eugene about Kaia’s founding, the company’s early decision to expand to the US (despite the different regulatory and payment environment), and his driving motivation to help chronic pain sufferers live longer, higher-quality lives. Also, Jonas mentions a McKinsey report on reimbursement in Germany, in which Kaia’s journey is offered as a brief case study. You can find that report here. >>Click here to read the transcript Guest Links and Resources: Connect with Jonas Duss: LinkedIn | Twitter Visit Kaia Health: Twitter | LinkedIn | Instagram | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

During his conscripted service with the German Navy, Christian Dierks learned that if you’re the person in charge of rules and administration, you can bring about a lot of change. He took this lesson with him to law school and in the creation of his own law and healthcare consultancy firm, Dierks+Company. Christian was instrumental in the creation of Germany’s 2019 Digital Health Care Act (known as DVG in Germany), which mandates full reimbursement of any prescribed digital health application. In fact, Christian was involved in setting up the legal framework for digital health applications (DiGA) in Germany—and importantly, he convinced health insurers in Germany not to nickname them DiVA, an acronym which would have carried distinctly less gravitas. Starting with this episode, Eugene says farewell (for now) to DTx trailblazers in the United States, and shifts the focus to leaders in Europe, where Christian and other thought leaders are working to broaden access to digital health solutions. Eugene and Christian recorded this episode in January, and since then, there have been some exciting updates to the status of DVG. Namely, the list of approved digital therapies for reimbursement has grown to 13, and Germany is starting to publish early data on the impact of the measure. >>Click here to read the transcript Guest Links and Resources: Connect with Christian Dierks: LinkedIn | Twitter Visit Dierks+Company: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Chris Wasden came to the digital therapeutics space via a circuitous route through Wall Street, Main Street, and academia. A pro at finding ways to leverage digital solutions in the pharmaceutical industry, he was asked to lead HappifyDTx’s digital therapeutics business after he and his students identified it as the best digital health company in the world. Happify just closed an impressive $73 million funding round and continues to innovate clinically validated tools to treat depression, anxiety, and sleep disorders. In this episode, Chris tells Eugene how Happify’s founders moved from creating video games to digital health tools, and why the team took on the mammoth effort of creating an FDA-quality management system for its platform of products. As a result of their hard work, Chris says Happify is the only DTx company out there that has a legitimate, placebo-controlled RCT. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Wasden: LinkedIn | Twitter Visit Happify Health: Twitter| LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Corey McCann says he always wanted to name a company after a fruit, and when he and his team saw an opportunity to “pair” drugs and software to treat serious disease and improve patient outcomes, the name Pear Therapeutics was born. Of course, the other inspiration for the creation of Pear Therapeutics was Genentech, in that Corey and his team wanted to build something big and capitalize on the hundreds of opportunities they see to modify standards of efficacy with software solutions. Corey, Eugene, and Brian talk about Pear’s early foray into the digital therapeutics space and how Pear’s digital therapies incorporate doctors, nurses, health coaches, and other human counselors. Also, for any entrepreneurs looking to start their own venture, Corey has several pearls of wisdom for you—one of which is to choose your investors and board members very wisely. Finally, Corey offers his predictions about the future of prescription digital therapeutics and the policy solutions needed to make PDTs viable for all patients. >>Click here to read the transcript Guest Links and Resources: Connect with Corey McCann: LinkedIn | Twitter Visit Pear Therapeutics: Twitter| LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Ask Chris Bergstrom what gets him out of bed in the morning, and he says very simply: “scale, scale, scale.” Chris brings a powerful blend of experience in start-ups, large companies, and the life sciences to his role as president of Amalgam Rx, a digital platform that brings providers and life sciences companies together to grow digital health solutions. Chris and Eugene talk about Amalgam’s origins and capabilities, and in response to a question from Brian Dolan about Amalgam’s recent acquisition of Avhana Health, Chris reveals that Amalgam has been lucky enough to start off as a fully self-funded venture. Finally, listen in as Chris and Eugene discuss whether the term “digital therapeutic” has become passé. >>Click here to read the transcript Guest Links and Resources: Connect with Chris Bergstrom: LinkedIn Visit Amalgam Rx: LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

As an engineer, Melinda Decker could have designed widgets or Styrofoam cups or even gone into winemaking. But her passion for improving patient outcomes led her to digital therapeutics, and eventually to Mymee, a direct-to-consumer platform that helps people with autoimmune disorders manage their symptoms. Mymee recognizes that behavior change is hard, so they combine a user-friendly app and data analytics with health coaching, to help users identify their triggers and make long-lasting lifestyle changes that lessen the severity of their symptoms and improve their overall health. Since its founding in 2017, Mymee has collaborated on two publications and recently closed a funding round of $8.7 million. Join Eugene and Melinda’s conversation about digital therapeutics vs. disease management and the path the Mymee team took to getting their solution off the ground. >>Click here to read the transcript Guest Links and Resources: Connect with Melinda Decker: LinkedIn Visit Mymee: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

When Peter Hames struggled with insomnia, he couldn’t get access to any treatment other than sleeping pills. Out of “desperation,” he said, Peter self-administered a cognitive behavioral therapy (CBT) course and within weeks was sleeping like a baby. That experience led to the development of Sleepio, an app which uses artificial intelligence to deliver digital cognitive behavioral therapy to improve user's sleep. I Peter applied his background in experimental psychology and technology to co-found Big Health, a digital therapeutics (DTx) company whose mission is to “help millions back to good mental health.” With 53 peer-reviewed papers and 13 randomized control trials, Big Health is also one of the only DTx companies in the world with an evidence base of its size, rigor, and quality. Join Eugene and Peter as they talk about the early days of digital therapeutics, Big Health’s unique direct-to-consumer approach in the UK and the US, and its deep-rooted commitment to clinical evidence and supporting science. May 20, 2022 News Update: National Institute for Health and Care Excellence recommends the use of Sleepio for treatment of insomnia when compared to pills or other methods Read more on the Telegraph: Trouble sleeping? Doctors will prescribe an app now instead of pills >>Click here to read the transcript Guest Links and Resources: Connect with Peter Hames: LinkedIn Visit Big Health: Twitter | LinkedIn | Website Learn more about Sleepio Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics. Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question. >>Click here to read the transcript Guest Links and Resources: Connect with Brent Vaughan: LinkedIn Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Follow Eugene's journey of writing his first book: Hard Pill to Swallow Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In this episode, I speak with Ed Cox, who is an Executive Vice President of Strategic Alliances and Global Head of Digital Medicines at EVERSANA. In our conversation, we focus on his journey through Dthera and the many lessons learned.  But before we dive in: Those of you who know Ed, will agree, he is a memorable guy, and therefore I am super surprised I can not even remember where we first met but what I do know is that every time I speak with Ed, I feel like I have known him my whole life.   >>Click here to read the transcript Be sure to check out my previous episode where I spoke with David Klein, CEO and Founder of Click Therapeutics - a company that was started in 2012 as a smoking cessation app and now with a pipeline of DTx therapies and a $500M deal with Boehringer Ingelheim.  Guest Links and Resources: Connect with Edward Cox: LinkedIn Visit EVERSANA : Twitter | LinkedIn | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In the last episode, I had the pleasure of speaking with Eddie Martucci, CEO and Founder of Akili Interactive - the creators of EndeavourRx, which is the first and only prescription treatment delivered through a video game. Imagine that! In this episode, I continue my DTx journey with yet another early trailblazer, David Klein, CEO and co-founder of Click Therapeutics. I first met David at Frontiers Health conference a few years back. He struck me as cool and composed, with a clear vision. Tune in as David shares a little bit of his background and how did he come to starting Click Therapeutics back in the day. >>Click here to read the transcript Guest Links and Resources: Connect with David Klein: LinkedIn Visit Click Therapeutics: Twitter | LinkedIn | Facebook | Instagram | Website Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

On the last episode, I got to know Anand Iyer, Chief Strategy Officer at WellDoc, who was instrumental in getting the Digital Therapeutics Alliance up and running. In this episode, the focus on the early trailblazers of the DTx industry continues with Eddie Martucci. Eddie is the CEO and founder of Akili Interactive, which has taken a super interesting go to market approach. I very briefly met Eddie, at a small event during the JPMorgan conference in San Francisco years ago. Eddie's energy and passion for the product exuded while he was showing a crowd of onlookers an early version of a game that is now an actual digital therapy, EndeavorRx Click here to read the transcript Guest Links and Resources: Connect with Eddie Martucci: Twitter | LinkedIn Visit Akili Interactive Labs Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In this episode, we speak with another one of the early trailblazers of the DTx industry, Anand Iyer, the Chief Strategy Officer of Welldoc. I briefly met Anand at a Health XL event in New York City early in 2019, even though Welldoc has been around since 2008. I'm not even sure how we did not run into each other before, but it was great to connect with Anand for this podcast and get to know him and what drives him, not to mention speak about the early days of Welldoc and DTx industry. Click here to read the transcript Guest Links and Resources: Connect with Anand Iyer: Twitter | LinkedIn Visit Welldoc Host Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In this episode, we speak with one of the founding members of the Digital Therapeutics Alliance ('DTA'), Pierre Leurent. Pierre is the CEO and founder of Voluntis, which is the first publicly listed DTx company on Euronext in Paris. Pierre co-founded Voluntis in 2001 with the mission to improve patients’ experience with their treatment thanks to digital technologies. Now, 20 years later, they have supported more than 600,000 patients and deployed over 50 programs around the world. Pierre is a Director of the Digital Therapeutics Alliance, of which he served as Chairman, and a member of Advamed’s Digital Health Executive Leadership Group. He previously co-chaired the digital therapeutics task force of the Personal Connected Health Alliance, a member of HIMSS, and chaired the eHealth France Alliance regrouping several leading trade organizations representing digital and life sciences companies in France. Pierre holds a MS from Ecole Centrale Paris. Links and Resources: Connect with Pierre Leurent: Twitter | LinkedIn Visit Voluntis Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In the previous episode in this two-part deep dive inside the Digital Therapeutics Alliance, I spoke to Megan Coder, the Executive Director for the DTA. In this episode, I'm excited to chat with Jessica Shull, European lead for the DTA. I met Jessica and Sitges, Spain near Barcelona at a HIMSS EU Health 2.0 event. Jessica struck me as sharp, composed and super knowledgeable, and of course, a great addition to the DTA. With Jessica's leadership, the DTA expanded its coverage across Europe, LATAM and Australia. Click here to read the transcript Links and Resources: Connect with Jessica Shull: Twitter | LinkedIn Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn HealthXL: Website | Twitter | Join an Event Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In the previous episode, Brian Dolan and I discussed the definition of digital therapeutics. The term 'digital therapeutics' has been used since about 2012, and in 2017 the Digital Therapeutics Alliance, aka DTA, came on the scene. In this two-part deep dive we go inside the DTA and in this episode, we start with Megan Coder, the Executive Director. I remember meeting the energetic, polished, and absolutely no BS, Megan, at the 2017 Frontiers Health in Berlin - yes, when face-to-face conferences were still a thing. At that conference, the DTA was officially launched. I strongly believe this was a historic moment for the overall industry. Click here to read the transcript Links and Resources: Connect with Megan Coder: Twitter Visit the Digital Therapeutics Alliance Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Eugene kicks off the Digital Therapeutics Podcast with journalist and entrepreneur Brian Dolan. Eugene met Brian way back in the pre-iphone days of 'mobile health' (that was before apps, before 4G, before tablets). In this episode, Brian describes how the need for innovation in tech and health led him to create MobiHealthNews. After selling MobiHealthNews to HIMSS in 2015, and is now is the founder and lead writer of Exits and Outcomes. A self-described 'fanboy' of Exits & Outcomes, Eugene invited Brian to be his sparring partner on this limited podcast series. Tune in as they dive into the past, present and future to uncover the truth about Digital Therapeutics. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

In this episode, I have the pleasure of introducing you to one of the health sectors leading innovators, and probably one of the best known and, dare I say it, most loved, leaders I’ve had the pleasure of knowing in my 20 plus years working in healthcare: Eugene Borukhovich. He’s a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the Chairman and Founding Board Member at YourCoach.Health and founder of Initium Impact Ventures.  Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer. He has also co-founded and sold a doctor rating startup and a consulting company. Eugene recently relocated to Barcelona where he enjoys running, writing, traveling and spending time with his family. Click here to read the transcript Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche

Join host Eugene Borukhovich as he explores how non-molecular therapies and interventions can prevent, manage or even cure diseases. In this limited series produced with Digital Health Today, learn about the rapidly evolving field of Digital Therapeutics, its history, the evolving regulatory and reimbursement frameworks, and the trailblazers creating and advancing this industry.